TY - JOUR AU - Wolff, Johannes M. AU - Schmid, Hans-Peter PY - 2012 TI - Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab JF - Translational Andrology and Urology; Vol 1, No 2 (June 30, 2012): Translational Andrology and Urology Y2 - 2012 KW - N2 - Denosumab is a human monoclonal antibody (IgG2) that binds to RANK ligand (RANKL). It reduces osteoclasts and thereby decreases bone resorption and cancer-induced bone destruction. UR - https://tau.amegroups.org/article/view/696